• 
• http://www.nature.com/leu
• Editor: Dr Nicole Muller-Bérat Killman
• Volume 22: 12 issues per year
• ISSN: 0887-6924
• EISSN: 1476-5551
• Impact factor : 6.924*
• Impact ranking: 13/132 in Oncology; 6/63 in Hematology*
• Date Established: 1987
• Published on behalf of:

Aims and Scope:

Leukemia covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance. Topics of interest are studies on oncogenes, growth factors, stem cells, gene transfer chromosomes, cell cycle, receptors, cell and membrane markers, and more.

Readership:
Researchers and clinicians in the fields of hematology and oncology.

Leukemia provides:

• Original Articles - high-quality, peer-reviewed, leukemia and allied diseases.
• Reviews - commissioned from leaders in the field, Reviews vary in length depending on the topic addressed. All reviews are supplemented with glossary explanations and highlighted references that are accompanied by an explanation as to why these references are essential reading.
• Letters to the Editor -correspondence between readers, authors, and the community. Letters to the editor deal with subjects that have recently been addressed in the journal or can introduce new topics.
• Meeting Reports - provides background information on recent meetings relevant to leukaemia and related areas. These manuscripts describe information presented by the speakers and summarise their key points.
• Keynote Address - Overviews by an expert in the field, providing the state of research at this point in time and the author's personal views for the future.
• Commentaries - a popular forum for provocative debate which gives experts a means by which to discuss, consider, and argue their cases.
• Research Highlights - these short articles highlight exciting primary articles published in Leukemia on a monthly basis.

What makes Leukemia stand apart from the rest of the competition?

• Spotlights - Leukemia spotlights focus on topical research in the field and contain both reviews and original manuscripts. These fields include Angiogenesis, Imatinib as a Model for Signal Transduction Inhibitors, Signal Transduction Inhibitors, Molecular Targeted Therapy, Chronic Lymphocytic Leukemia, Stem cells and Acute Promyelocytic.
• Experience in the field - 2007 marks Leukemia's 20th year in providing the science community with the most crucial research and advances in leukemia and allied diseases. Throughout 2007 Leukemia will offer special promotions, including FREE access to selected articles from current and past issues.
• FREE archive accessibility - Free to all readers, the complete text of all articles in the back archive four years after publication; tables of contents and abstracts for all articles published since 1997 and the complete text of the January issue of corresponding year.
• Online features at your fingertips - Easy access to the research you need at any time, including:
  • Electronic manuscript submission via eJournal Press
  • Full-text HTML articles with links to MEDLINE and CrossRef
  • PDF versions of all articles for easy printing
  • Free access to research abstracts
  • Free selected articles each week
  • Free Table of Contents e-alerts service

Online features and site license access:

• Online archive available back to January 1997.
• A site license provides access to all content published during the supply period. Access is granted to a further rolling four-year archive during the supply period only. Archive content is freely available after five years.
• Users have access to all the online features of nature.com. Find out more >>
• Site license customers will benefit from the services available. Find out more >>
• Indexed in Medline (PubMed), Current Contents Life Sciences, Elsevier BIOBASE/Current Awareness in Biological Sciences, EMBASE, Research Alert, Cambridge Scientific Abstracts, BIOSIS, Reference Update, SUBIS, SciExpanded, Current Advances in Cell and Developmental Biology and Current Advances in Genetics and Molecular Biology.

*2007 Journal Citation Report (Thomson Reuters, 2008)